Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don G Morris

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Investigational New Drugs|August 14, 2012
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumorsDon G Morris, Xiaolan Feng, Lisa M DiFrancesco, et al.
Journal of the National Cancer Institute|March 30, 2019
Association of Indoor Tanning Exposure With Age at Melanoma Diagnosis and BRAF V600E MutationsToni E Burbidge, Boris C Bastian, Danny Guo, et al.
Sarcoma|January 26, 2007
A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue SarcomaDon G Morris, Vivien H C Bramwell, Robert Turcotte, et al.
Cancers|June 20, 2018
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast CancerAhmed A Mostafa, Daniel E Meyers, Chandini M Thirukkumaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
Reovirus as a viable therapeutic option for the treatment of multiple myelomaChandini M Thirukkumaran, Zhong Qiao Shi, Joanne Luider, et al.
Autophagy|January 17, 2013
Reovirus modulates autophagy during oncolysis of multiple myelomaChandini M Thirukkumaran, Zhong Qiao Shi, Joanne Luider, et al.
Frontiers in Immunology|July 3, 2024
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancerAnnalise G Abbott, Daniel E Meyers, Golpira Elmi-Assadzadeh, et al.
JAMA Network Open|January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsSarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Cancers|May 14, 2022
Combining TMEM Doorway Score and Mena<sup>Calc</sup> Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2- Breast Cancer PatientsXianjun Ye, Maja H Oktay, Xiaonan Xue, et al.
Cancer Medicine|March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitorsMichael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Investigational New Drugs|August 14, 2012
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumorsDon G Morris, Xiaolan Feng, Lisa M DiFrancesco, et al.
Journal of the National Cancer Institute|March 30, 2019
Association of Indoor Tanning Exposure With Age at Melanoma Diagnosis and BRAF V600E MutationsToni E Burbidge, Boris C Bastian, Danny Guo, et al.
Sarcoma|January 26, 2007
A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue SarcomaDon G Morris, Vivien H C Bramwell, Robert Turcotte, et al.
Cancers|June 20, 2018
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast CancerAhmed A Mostafa, Daniel E Meyers, Chandini M Thirukkumaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
Reovirus as a viable therapeutic option for the treatment of multiple myelomaChandini M Thirukkumaran, Zhong Qiao Shi, Joanne Luider, et al.
Autophagy|January 17, 2013
Reovirus modulates autophagy during oncolysis of multiple myelomaChandini M Thirukkumaran, Zhong Qiao Shi, Joanne Luider, et al.
Frontiers in Immunology|July 3, 2024
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancerAnnalise G Abbott, Daniel E Meyers, Golpira Elmi-Assadzadeh, et al.
JAMA Network Open|January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsSarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Cancers|May 14, 2022
Combining TMEM Doorway Score and Mena<sup>Calc</sup> Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2- Breast Cancer PatientsXianjun Ye, Maja H Oktay, Xiaonan Xue, et al.
Cancer Medicine|March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitorsMichael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.
Pageof 3